FDA Approvals - Insmed Incorporated Provides Regulatory Update on ARIKACE in Non-Tuberculous Mycobacteria
Insmed Incorporated Provides Regulatory Update on ARIKACE in Non-Tuberculous Mycobacteria Indication
Insmed Incorporated , a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trial for ARIKACE in patients with non-tuberculous mycobacterial lung disease.